---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-037161"
form_type: "8-K"
ticker: "ERAS"
cik: "0001761918"
company_name: "Erasca, Inc."
filed_at: "2024-03-27T23:59:59+00:00"
generated_at: "2026-06-04T07:18:25.860415+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Erasca reports FY2023 net loss $125M, cash $322M; clinical updates for naporafenib and ERAS-801

## Summary
- Net loss $125M ($0.83/share) for FY2023 vs $242.8M ($1.99/share) in prior year; R&D expenses $103.8M.
- Cash, equivalents, marketable securities $322M as of Dec 31, 2023, down from $435.6M.
- Gained FDA Fast Track Designation for naporafenib + trametinib in NRASm melanoma; planned Phase 3 SEACRAFT-2 initiation H1 2024.
- Entered clinical trial collaboration with Novartis for trametinib supply for naporafenib trials at no cost.
- Multiple data readouts expected in 2024 for naporafenib (SEACRAFT-1), ERAS-007 (HERKULES-3), ERAS-801 (THUNDERBBOLT-1).

## SEC filing metadata
- accession: 0000950170-24-037161
- form_type: 8-K
- ticker: ERAS
- cik: 0001761918
- company_name: Erasca, Inc.
- filed_at: 2024-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761918/000095017024037161/0000950170-24-037161-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761918/000095017024037161/eras-20240327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-037161
- JSON: https://secwatch.observer/filing/0000950170-24-037161.json
- Plain text: https://secwatch.observer/filing/0000950170-24-037161.txt

## Key facts
- Earnings Releases
  Erasca, Inc. reported financial results for the fiscal quarter and full year ended December 31, 2023.
  - Period: the fiscal quarter and full year ended December 31, 2023
  - Result: reported results
  source text: On March 27, 2024, Erasca, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1761918/000095017024037161/0000950170-24-037161-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.